We are live on ! Find out more

32 hedge funds and large institutions have $2.95M invested in PAVmed in 2025 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 7 increasing their positions, 3 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

302% more capital invested

Capital invested by funds: $735K → $2.95M (+$2.22M)

200% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 2

133% more repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 3

14% more funds holding

Funds holding: 2832 (+4)

0% more ownership

Funds ownership: 0.24%0.24% (+0%)

Holders
32
Holders Change
+4
Holders Change %
+14.29%
% of All Funds
0.42%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
6
Increased
7
Reduced
3
Closed
2
Calls
Puts
Net Calls
Net Calls Change

PAVM Hedge Fund Activity: Q3 2025 in Review

32 of the 7,625 institutional investors tracked by Wall St. Rank reported a position in PAVmed (PAVM) for Q3 2025, worth a combined $2.95M — up 302% from $735K a quarter earlier.

Buyers outnumbered sellers: 6 funds opened new PAVM positions and 2 closed out — a net gain of 4 holders — while 7 added to existing stakes and 3 trimmed.

The largest buyer was Vanguard Group, adding an estimated $62.9K. The largest seller was UBS Group, cutting an estimated $3.91K.

  • 32 institutional investors held PAVmed (PAVM) as of Q3 2025, up from 28 in Q2 2025.
  • Funds reported $2.95M of PAVmed stock for Q3 2025, up 302% quarter-over-quarter.
  • 6 funds opened new PAVmed positions in Q3 2025 and 2 closed out, a net change of +4 holders.
  • The largest PAVmed buyer in Q3 2025 was Vanguard Group, an estimated $62.9K added.
  • The largest PAVmed seller in Q3 2025 was UBS Group, an estimated $3.91K sold.

Based on aggregated 13F filings for Q3 2025.